KRAS and fibrosis: However, the result reported on here do not support the findings of previous research on hard-to-treat patients who were prior DAA exposed with virological failure, the majority of patients with cirrhosis or severe fibrosis, the frequent presence of NS5A and NS3 resistance-associated variants (RAVs) at baseline, these had received EBR/GZR and SVR12 was achieved 96% (Buti et al., 2016; de Lédinghen et al., 2018).